ASHLAND INC. COMMON STOCK

Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program

31 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Ashland sets date for fiscal 2022 fourth-quarter earnings release and conference call webcast

25 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Ashland launches 2021 Environment, Social and Governance Report in preparation for releasing Science Based Targets for UN Compact

17 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Ashland increases prices up to 15 percent due to inflation-related costs

21 Sep 2022 17:00:00 By Nasdaq GlobeNewswire

Ashland announces expansion of Viatel™ bioresorbable polymers manufacturing and R&D capabilities in Mullingar, Ireland

30 Aug 2022 17:00:00 By Nasdaq GlobeNewswire